The economics of genomics
基因组的经济学
The arguments ranged beyond the arcana of human genetics and American patent law.
讨论范围超出了人类遗传学的深奥知识和美国专利法之外。
The judges were keen to explore the impact of a hypothetical anti-Myriad ruling on thecountry s thriving biotechnology industry, which, according to one estimate, was worth 92billion in 2011.
法官们热衷于探讨的是,一个假设的反对麦利亚德公司专利的裁决会对国家日益繁荣的生物技术行业产生何种影响,据统计,生物技术行业2011年产值为920亿美元。
Several questioned Christopher Hansen, the plaintiffs lawyer, on what incentive firms wouldhave to identify interesting genes if there were no possibility of winning a patent on them.
有人质疑原告律师克里斯多夫汉森,如果不能获得专利权,那么公司又有什么动力去发掘有价值的基因。
Developing such tests is not cheap.
基因测序技术的实验花费并不便宜。
According to Mark Capone, Myriad s president, the firm spent around 500m before it had aproduct it could bring to market.
据麦利亚德公司董事长马克卡波尼所说,公司在一个生物产品可投入市场之前要花费大概5亿美元。
【2015考研英语阅读生物技术专利】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30